711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy

Published 2020 View Full Article

Authors

Keywords

Journal

ANNALS OF ONCOLOGY

Volume 31, Issue -, Pages S559-S560

Publisher

Elsevier BV

Online

2020-09-22

DOI

10.1016/j.annonc.2020.08.783

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

ANNALS OF ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Find Funding. Review Successful Grants.

Publish scientific posters with Peeref